BRNS Barinthus Biotherapeutics Plc.

Price (delayed)

$0.7

Market cap

$28.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.29

Enterprise value

-$27.59M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 9

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed ...

Highlights
The net income has grown by 21% from the previous quarter and by 20% YoY
Barinthus Biotherapeutics's EPS has increased by 21% from the previous quarter and by 21% YoY
The gross profit has dropped by 100% year-on-year
BRNS's revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of BRNS

BRNS stock price

How has the Barinthus Biotherapeutics stock price performed over time
Intraday
-0.11%
1 week
2.46%
1 month
10.24%
1 year
-30.69%
YTD
-0.01%
QTD
23.02%

Financial performance

How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.03M
Net income
-$52.31M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
BRNS's revenue has dropped by 100% year-on-year
BRNS's operating income is up by 22% YoY and by 21% from the previous quarter
The net income has grown by 21% from the previous quarter and by 20% YoY

Price vs fundamentals

How does BRNS's price correlate with its fundamentals

Growth

What is Barinthus Biotherapeutics's growth rate over time

Valuation

What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Barinthus Biotherapeutics's EPS has increased by 21% from the previous quarter and by 21% YoY
The stock's price to book (P/B) is 39% less than its 5-year quarterly average of 0.7 but 8% more than its last 4 quarters average of 0.4
The equity has contracted by 11% from the previous quarter and by 11% YoY
BRNS's revenue has dropped by 100% year-on-year

Efficiency

How efficient is Barinthus Biotherapeutics business performance
BRNS's return on assets is up by 20% since the previous quarter but it is down by 8% year-on-year
The return on equity has increased by 19% since the previous quarter but it has declined by 14% year-on-year
Barinthus Biotherapeutics's return on invested capital has increased by 18% QoQ

Dividends

What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BRNS.

Financial health

How did Barinthus Biotherapeutics financials performed over time
Barinthus Biotherapeutics's quick ratio has decreased by 22% from the previous quarter and by 22% YoY
The current ratio fell by 22% QoQ and by 22% YoY
The debt is 83% lower than the equity
BRNS's debt to equity is up by 13% since the previous quarter and by 13% year-on-year
The equity has contracted by 11% from the previous quarter and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.